source
- Ethyreal Bio secures $101M to develop treatments for Graves' disease and thyroid eye diseaseEthyreal Bio, a newly unveiled biotech, announced it has raised $101 million in financing. The round was led by venture firms Atlas Venture and Medicxi. The capital will be used to advance therape…
- Sanofi halts Phase 3 trial of riliprubart in rare neurological disorderSanofi announced it is ending the Phase 3 study of its antibody drug riliprubart aimed at treating a rare neurological disease. The decision follows a recommendation from an independent data monit…